The purpose of the study is to assess the efficacy, safety and tolerability of NGX 4010 applied for 60 minutes for the treatment of PHN.

Condition	Treatment or Intervention	Phase
Herpes Zoster Neuralgia Pain Peripheral Nervous System Diseases	Drug: Capsaicin Dermal Patch	Phase III

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• At least 18 years of age.
• Be in good health.
• Diagnosis of postherpetic neuralgia (PHN) made by the primary treating physician or Investigator, and at least 3 months post-vesicle crusting.
• Screening Pain Sum Score of 12 to 36.
• Intact, unbroken skin over the painful area(s) to be treated.
• If taking chronic pain medications, be on a stable (not PRN) regimen for at least 21 days prior to Treatment Visit (Day 0) and willing to maintain medications at same stable dose(s) and schedule throughout the study.
• Female subjects with child-bearing potential must have a negative serum beta hCG pregnancy test, to be performed at the Screening Visit.
• All subjects must be willing to use effective methods of birth control and/or refrain from participating in a conception process during the study and for 30 days following experimental drug exposure.
• Be willing and able to comply with protocol requirements for the duration of study participation. (Such requirements include, but are not limited to: completing a daily pain diary, attending all study visits, and refraining from elective surgery and extensive travel during study participation.)

Exclusion Criteria:

• Concomitant opioid medication, unless orally or transdermally administered and not exceeding a total daily dose of morphine 60 mg/day, or equivalent. Parenteral opioid use is excluded, regardless of dose.
• Unavailability of an effective rescue medication strategy for the subject, such as unwillingness to use opioid analgesics during treatment, or high tolerance to opioids precluding the ability to relieve treatment-associated discomfort with Roxicodone®, as judged by the Investigator.
• Active substance abuse or history of chronic substance abuse within the past year, or prior chronic substance abuse judged likely to recur during the study period by the investigator.
• Recent use (within 21 days preceding the Treatment Visit [Day 0]) of any topically applied pain medication, such as non-steroidal anti-inflammatory drugs, menthol, methyl salicylate, local anesthetics (including Lidoderm®), steroids or capsaicin products on the painful areas.
• Current use of any investigational agent, or Class 1 anti-arrhythmic drugs (such as tocainide and mexiletine).
• Significant pain of an etiology other than PHN, for example, compression-related neuropathies (e.g., spinal stenosis) or fibromyalgia or arthritis. Subjects must not have significant ongoing pain from other cause(s) that may interfere with judging PHN-related pain.
• Painful PHN areas located only on the face, above the hairline of the scalp, and/or in proximity to mucous membranes. (Investigational treatment with NGX-4010 is not allowed in these areas.)
• Any implanted medical device (spinal cord stimulator, intrathecal pump or peripheral nerve stimulator) for the treatment of neuropathic pain.
• Hypersensitivity to capsaicin (i.e., chili peppers or Over-the-Counter (OTC) capsaicin products), local anesthetics, Roxicodone® or adhesives.
• Significant ongoing or untreated abnormalities in cardiac, renal, hepatic, or pulmonary function that may interfere either with the ability to complete the study or the evaluation of adverse events.

Arizona
      Pivotal Research Center, Peoria,  Arizona,  85381,  United States
      Hope Research Institute, Phoenix,  Arizona,  85032,  United States
      Pivotal Research Center, Mesa,  Arizona,  85210,  United States
California
      Advanced Pain Institute, Duarte,  California,  91010,  United States
      Kaiser Permanente, Santa Rosa,  California,  95403,  United States
Florida
      Anchor Research Center, Naples,  Florida,  34102,  United States
      Comprehensive Neuroscience, Inc., Boynton Beach,  Florida,  33437,  United States
      CNS Clinical Trials, Fort Myers,  Florida,  33907,  United States
      Tampa Medical Group, Tampa,  Florida,  33614,  United States
      Bradenton Neurology, Inc., Bradenton,  Florida,  34205,  United States
Georgia
      Comprehensive NeuroScience, Inc., Atlanta,  Georgia,  30328,  United States
      Georgia Medical Research Institute, Marietta,  Georgia,  30060,  United States
Massachusetts
      Boston Clinical Trials, Brighton,  Massachusetts,  02135,  United States
Missouri
      Healthcare Research LLC, St. Louis,  Missouri,  63141,  United States
      Medex Healthcare Research, St. Louis,  Missouri,  63108,  United States
North Carolina
      The Center for Clinical Research, Winston Salem,  North Carolina,  27103,  United States
Texas
      Progressive Clinical Research, San Antonio,  Texas,  78229,  United States
      Renaissance Clinical Research And Hypertension Clinic, Dallas,  Texas,  75235,  United States
Utah
      Lifetree Clinical Research, Salt Lake City,  Utah,  84107,  United States

Study ID Numbers:  C110
Record last reviewed:  November 2004
Last Updated:  November 15, 2004
Record first received:  September 5, 2003
ClinicalTrials.gov Identifier:  NCT00068081
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08